USS Investment Management Ltd Sells 9,405 Shares of Danaher Co. (NYSE:DHR)

USS Investment Management Ltd lowered its position in shares of Danaher Co. (NYSE:DHR) by 6.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 126,149 shares of the conglomerate’s stock after selling 9,405 shares during the quarter. USS Investment Management Ltd’s holdings in Danaher were worth $28,966,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of DHR. Merit Financial Group LLC grew its stake in Danaher by 14.3% in the 4th quarter. Merit Financial Group LLC now owns 10,050 shares of the conglomerate’s stock valued at $2,307,000 after buying an additional 1,260 shares in the last quarter. Ameritas Advisory Services LLC grew its position in shares of Danaher by 17.2% during the 4th quarter. Ameritas Advisory Services LLC now owns 1,238 shares of the conglomerate’s stock valued at $284,000 after purchasing an additional 182 shares in the last quarter. Hall Laurie J Trustee grew its position in shares of Danaher by 5.2% during the 4th quarter. Hall Laurie J Trustee now owns 21,669 shares of the conglomerate’s stock valued at $4,974,000 after purchasing an additional 1,065 shares in the last quarter. Diversify Wealth Management LLC grew its position in shares of Danaher by 7.8% during the 4th quarter. Diversify Wealth Management LLC now owns 8,186 shares of the conglomerate’s stock valued at $1,924,000 after purchasing an additional 592 shares in the last quarter. Finally, Mechanics Bank Trust Department grew its position in shares of Danaher by 14.8% during the 4th quarter. Mechanics Bank Trust Department now owns 9,233 shares of the conglomerate’s stock valued at $2,119,000 after purchasing an additional 1,193 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. UBS Group cut their target price on shares of Danaher from $275.00 to $240.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. Raymond James reissued a “market perform” rating on shares of Danaher in a research note on Monday, February 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, April 23rd. Barclays boosted their price target on shares of Danaher from $205.00 to $215.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 22nd. Finally, Citigroup reissued a “buy” rating on shares of Danaher in a research note on Monday, April 7th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $264.40.

Danaher Stock Up 0.1%

DHR opened at $196.33 on Tuesday. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a market capitalization of $140.51 billion, a PE ratio of 37.18, a PEG ratio of 2.66 and a beta of 0.80. The firm’s 50 day simple moving average is $196.69 and its two-hundred day simple moving average is $216.91.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. As a group, equities analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. Danaher’s dividend payout ratio is presently 24.85%.

Insider Buying and Selling

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now owns 15,179 shares of the company’s stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business’s stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.